US diabetes care drugs market is anticipated to grow significantly over the forecast period (2020-2026). The key factor that drives the growth of the market includes the presence of a large pool of patients suffering from diabetes in the country. As per International Diabetes Federation, the number of adults suffering from diabetes in the country was 31.0 million peoples in 2019, which is projected to reach up to 34.4 million peoples in 2030, which is further predicted to reach 36.0 million in 2045.
Browse the full report description US Diabetes Care Drugs Market Size, Share & Trends Analysis Report by Drug Class (Insulins, Non-Insulin Injectable Drugs, Oral Anti-Diabetic Drugs, and Combination Drugs) Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/us-diabetes-care-drugs-market
Hence, the increased cases of diabetes are likely to prompt the demand for the proper treatment, which in turn, will provide growth opportunities for the US diabetes care drugs industry to grow in the near future.
Further, the government and other organizational support, to create awareness regarding the treatment and early diagnosis of the disease is also expected to propel the growth of the US diabetes care drugs market over the forecast period. Some of the awareness programs include the National Diabetes Prevention Program, American Diabetes Association, and other Diabetes Awareness and Prevention Campaigns.
Furthermore, the footprints of major players operating in the market such as Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., Merck & Co. Inc., Novartis International AG, Novo Nordisk A/S, Pfizer Inc., Sanofi SA, Takeda Pharmaceuticals Industries Ltd. among others support the market growth.
Market Coverage
Key questions addressed by the report
US Diabetes Care Drugs Market – Segmentation
By Drug Class
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/us-diabetes-care-drugs-market